3+ day, 17+ hour ago   (271+ words) Here’s why stem cell transplants belong in a longevity conversation at all: they are, in large part, a disease of getting older. The patients who need them skew heavily toward late middle age and beyond, and as the global population…...

4+ day, 17+ hour ago   (466+ words) Moonwalk CEO and cofounder Alex Aravanis told Longevity.Technology that the company believes its preclinical body-composition findings arise from acting directly on adipose rather than indirectly through appetite. “Our approach is fundamentally different because MW101 is designed to act directly on…...

5+ day, 17+ hour ago   (412+ words) Biotech real estate has its own hierarchy, and San Diego sits near the top. So when a Seongnam-based RNA therapeutics company buys itself a desk inside Eli Lilly’s newest innovation outpost there, it’s worth asking what that access is actually…...

6+ day, 19+ hour ago   (344+ words) Deals in cell therapy tend to get announced in two flavors: the kind built around a single drug, and the kind built around infrastructure. This unglamorous plumbing decides whether any of these therapies can actually be made at scale. The…...

1+ week, 4+ day ago   (247+ words) Patents rarely make headlines outside the biotech trade press, but for a clinical-stage company preparing to enter a pivotal trial, a strong patent estate can matter as much as the data itself. Alterity Therapeutics has just secured one of those…...

1+ week, 6+ day ago   (480+ words) Greenstone Biosciences, a Palo Alto biotech built around a biobank of more than 2,500 donor-derived induced pluripotent stem cell (iPSC) lines, has just received fresh federal backing to test whether skipping the animal step altogether can produce better drugs, faster [1]. The…...

2+ week, 5+ day ago   (260+ words) Ten million dollars landed in AlzeCure Pharma’s account this week. It’s not a huge number by pharma standards, but it’s the opening move in a deal that could eventually be worth more than a billion, and it says something about…...

3+ week, 4+ day ago   (869+ words) Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life. With a keen interest in all things geroscience,…...

3+ week, 5+ day ago   (287+ words) Small biotechs live and die by a brutal math problem: great science, not enough cash to prove it. AlzeCure Pharma, a Stockholm-listed company working on Alzheimer’s and pain, just solved that problem for at least one of its programs, and…...

4+ week, 2+ day ago   (1584+ words) Novo Nordisk’s phase 3 ZEUS failure has shaken the cardiovascular inflammation field. The result is significant not because it disproves inflammation as a driver of disease, but because it exposes thelimitations of a biomarker-led development strategy. It also had a direct…...